Dergiler / European Journal of Rheumatology / 2021 / Cilt: 8 - Sayı: 4

The association of anti-CD74 antibody with spondyloarthropathies

Sayfa
207–210
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: This study could not find an association between anti-CD74 levels and SpA in Turkish patients.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The etiopathogenesis of spondyloarthropathies (SpA) is still unclear.
📊
Temel Bulgular & Veri:Recently, anti-CD74 antibody has been suspected to play a role in SpA etiopathogenesis.
💡
Sonuç & Katkı:Conclusion: This study could not find an association between anti-CD74 levels and SpA in Turkish patients.
🔬Tür:Araştırma Makalesi
📍Kapsam:2013 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: The etiopathogenesis of spondyloarthropathies (SpA) is still unclear. Recently, anti-CD74 antibody has been suspected to play a role in SpA etiopathogenesis. This study aimed to examine the levels of anti-CD74 antibody in patients with SpA and investigate their association with disease activity. Methods: This study was conducted using data from patients who were treated at the departments of rheumatology and gastroenterology between June 2013 and November 2013. The demographic and clinical characteristics of the participants and their serum IgG-type antibodies against anti-CD74 were analyzed. Results: We analyzed 111 patients with ankylosing spondylitis (AS), 108 patients with inflammatory bowel disease (IBD), and 101 healthy controls. The rate of human leukocyte antigen–B27 positivity was 86.5% in patients with AS and 21.3% in patients with IBD. The mean levels of anti-CD74 antibodies in the AS, IBD, and control groups were 6.99±3.24 ng/mL, 6.25±3.34 ng/mL, and 7.83±4.72 ng/mL, respectively. Anti-CD74 levels were higher in healthy controls than in patients with IBD (P = .009). There was no significant difference in anti-CD74 levels between the AS and IBD groups and the AS and control groups. In addition, there was no correlation between anti-CD74 levels and disease activity. Conclusion: This study could not find an association between anti-CD74 levels and SpA in Turkish patients.

🔖

Bu Makaleye Atıf Yap

TURGAY, T. M., ÇOLAK, S., KÜÇÜKŞAHİN, O., DUMAN, M. T., TORUNER, M., ÇETİNKAYA, H. (2022). The association of anti-CD74 antibody with spondyloarthropathies. European Journal of Rheumatology, Cilt: 8 - Sayı: 4, 207–210. https://ajindex.com/articles/511492

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (16)

  1. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991
  2. [Crossref] 2. Podolsky D. Inflamatory bowel disease. N Engl J Med. 2002
  3. [Crossref] 3. Karreman MC, Luime JJ, Hazes JMW, Weel AEAM. The Prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2017
  4. [Crossref] 4. Bakland G, Nossent HC. Epidemiology of spondyloarthritis: a review. Curr Rheumatol Rep. 2013
  5. [Crossref] 5. Onen F, Akar S, Birlik M, Sari I. Prevalence of ankylosing spondylitis and related spondyloarthritides in an urban area of Izmir, Turkey. J Rheumatol. 2008
  6. Fallahi S, Jamshidi AR. Diagnostic delay in ankylosing spondylitis: related factors and prognostic outcomes. Arch Rheumatol. 2016
  7. [Crossref] 7. Sheehan NJ. HLA-B27: what’s new? Rheumatology (Oxford). 2010
  8. [Crossref] 8. Bowness P. Hla B27. Annu Rev Immunol. 2015
  9. [Crossref] 9. Fiorillo M, Haroon N, Ciccia F, Breban M. Editorial: ankylosing spondylitis and related immune- mediated disorders. Front Immunol. 2019
  10. [Crossref] 10. Stein R, Mattes MJ, Cardillo TM, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 2007
  11. 5556s-63s. [Crossref] 11. Becker-Herman S, Arie G, Medvedovsky H, Kerem A. CD74 is a member of the regulated intramembrane proteolysis-processed protein family. Mol Biol Cell. 2005
  12. [Crossref] 12. Maksymowych WP. Biomarkers in axial spondyloarthritis. Curr Opin Rheumatol. 2015
  13. [Crossref] 13. Boel A, Molto A, van der Heijde D, et al. Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. Ann Rheum Dis. 2019
  14. [Crossref] 14. Martins NA, Furtado GE, Campos MJ, Leitão JC, Filaire E, Ferreira JP. Exercise and ankylosing spondylitis with New York modified criteria: a systematic review of controlled trials with meta-analysis. Acta Reumatol Port. 2014
  15. Akkoc Y, Karatepe AG, Akar S, Kirazli Y, Akkoc N. A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity. Rheumatol Int. 2005
  16. [Crossref] 16. Machado P, Landewé R, Lie E, et al. Ank